Have a feature idea you'd love to see implemented?
Let us know!
CPRX Catalyst Pharmaceuticals Inc
Price (delayed)
$22.93
Market cap
$2.73B
P/E Ratio
18.34
Dividend/share
N/A
EPS
$1.25
Enterprise value
$2.3B
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK
Highlights
Catalyst Pharmaceuticals's net income has surged by 130% YoY and by 110% QoQ
The EPS has soared by 112% since the previous quarter and by 112% year-on-year
The stock's P/E is 22% less than its last 4 quarters average of 23.5 but 18% more than its 5-year quarterly average of 15.5
Key stats
What are the main financial stats of CPRX
Market
Valuations
Earnings
Shares outstanding
119.27M
Market cap
$2.73B
Enterprise value
$2.3B
Price to earnings (P/E)
18.34
Price to book (P/B)
4.12
Price to sales (P/S)
5.92
EV/EBIT
12.16
EV/EBITDA
10.13
EV/Sales
4.98
Revenue
$460.48M
Gross profit
$397.47M
Net income
$142.8M
EBIT
$188.79M
EBITDA
$226.52M
Free cash flow
$224.02M
Per share
Balance sheet
Liquidity
EPS
$1.25
EPS diluted
$1.18
Free cash flow per share
$1.88
Book value per share
$5.57
Revenue per share
$3.87
TBVPS
$5.1
Total assets
$772.01M
Total liabilities
$111.07M
Debt
$2.89M
Equity
$660.94M
Working capital
$433.6M
Debt to equity
0
Current ratio
5.11
Quick ratio
4.75
Net debt/EBITDA
-1.94
Margins
Efficiency
Dividend
EBITDA margin
49.2%
Gross margin
86.3%
Net margin
31%
Operating margin
37.8%
Return on assets
22%
Return on equity
25.7%
Return on invested capital
282%
Return on capital employed
28.3%
Return on sales
41%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CPRX stock price
How has the Catalyst Pharmaceuticals stock price performed over time
Intraday
0.04%
1 week
-0.56%
1 month
7.8%
1 year
51.35%
YTD
9.87%
QTD
9.87%
Financial performance
How have Catalyst Pharmaceuticals's revenue and profit performed over time
Revenue
$460.48M
Gross profit
$397.47M
Operating income
$173.97M
Net income
$142.8M
Gross margin
86.3%
Net margin
31%
Catalyst Pharmaceuticals's net income has surged by 130% YoY and by 110% QoQ
The company's operating income has surged by 129% YoY and by 103% QoQ
Catalyst Pharmaceuticals's net margin has surged by 97% QoQ and by 74% YoY
The operating margin has soared by 91% QoQ and by 73% YoY
Growth
What is Catalyst Pharmaceuticals's growth rate over time
Valuation
What is Catalyst Pharmaceuticals stock price valuation
P/E
18.34
P/B
4.12
P/S
5.92
EV/EBIT
12.16
EV/EBITDA
10.13
EV/Sales
4.98
The EPS has soared by 112% since the previous quarter and by 112% year-on-year
The stock's P/E is 22% less than its last 4 quarters average of 23.5 but 18% more than its 5-year quarterly average of 15.5
Catalyst Pharmaceuticals's equity has surged by 90% YoY and by 9% QoQ
The stock's price to book (P/B) is 14% more than its last 4 quarters average of 3.6 and 11% more than its 5-year quarterly average of 3.7
The revenue rose by 32% YoY and by 6% QoQ
The price to sales (P/S) is 29% higher than the last 4 quarters average of 4.6 and 26% higher than the 5-year quarterly average of 4.7
Efficiency
How efficient is Catalyst Pharmaceuticals business performance
The ROIC has soared by 109% since the previous quarter and by 8% year-on-year
The ROS has soared by 91% since the previous quarter and by 77% year-on-year
The ROE has soared by 80% from the previous quarter and by 40% YoY
CPRX's return on assets has surged by 80% since the previous quarter and by 46% year-on-year
Dividends
What is CPRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CPRX.
Financial health
How did Catalyst Pharmaceuticals financials performed over time
The total assets has soared by 87% year-on-year and by 9% since the previous quarter
The total liabilities has soared by 72% YoY and by 14% QoQ
Catalyst Pharmaceuticals's debt is 100% lower than its equity
CPRX's debt to equity has dropped by 100% year-on-year
Catalyst Pharmaceuticals's equity has surged by 90% YoY and by 9% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.